These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 16720854)

  • 21. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study.
    Fiorica JV; Blessing JA; Puneky LV; Secord AA; Hoffman JS; Yamada SD; Buekers TE; Bell J; Schilder JM;
    Gynecol Oncol; 2009 Nov; 115(2):285-9. PubMed ID: 19726073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid tumors.
    Hedde JP; Neuhaus T; Schüller H; Metzler U; Schmidt-Wolf IG; Kleinschmidt R; Losem C; Lange O; Grohe C; Stier S; Ko YD
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):839-44. PubMed ID: 17379446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale).
    Lorusso V; Galetta D; Giotta F; Rinaldi A; Romito S; Brunetti C; Silvestris N; Colucci G
    Anticancer Res; 2006; 26(3B):2259-63. PubMed ID: 16821598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer.
    Braly P; Nicodemus CF; Chu C; Collins Y; Edwards R; Gordon A; McGuire W; Schoonmaker C; Whiteside T; Smith LM; Method M
    J Immunother; 2009 Jan; 32(1):54-65. PubMed ID: 19307994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.
    Grabenbauer GG; Gerber KD; Ganslandt O; Richter A; Klautke G; Birkmann J; Meyer M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):164-9. PubMed ID: 19695435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
    Grønlund B
    Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase I trial of oxaliplatin and topotecan in recurrent ovarian carcinoma.
    Elkas JC; Winter WE; Chernofsky MR; Sunde J; Bidus MA; Bernstein S; Rose GS
    Gynecol Oncol; 2007 Feb; 104(2):422-7. PubMed ID: 16996118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous intravenous infusion of cytotoxic agents.
    Ostrowski MJ
    Nurs Times; 1979 May; 75(22):919-20. PubMed ID: 255965
    [No Abstract]   [Full Text] [Related]  

  • 30. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer.
    Maitland ML; Wilcox R; Hogarth DK; Desai AA; Caligiuri P; Abrahams C; Salgia R
    Lung Cancer; 2006 Nov; 54(2):243-5. PubMed ID: 16949700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
    Vergote I; Finkler N; del Campo J; Lohr A; Hunter J; Matei D; Kavanagh J; Vermorken JB; Meng L; Jones M; Brown G; Kaye S;
    Eur J Cancer; 2009 Sep; 45(13):2324-32. PubMed ID: 19515553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infusion nurses society position paper. Administration of antineoplastic agents.
    J Infus Nurs; 2002; 25(2):83-5. PubMed ID: 11984221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Devices for administering cancer drugs.
    McLaughlin-Hagan M
    AAOHN J; 1987 Apr; 35(4):172-4. PubMed ID: 2950888
    [No Abstract]   [Full Text] [Related]  

  • 34. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.
    Dalezis P; Geromichalos GD; Voyatzi S; Trafalis D; Athanassiou AE; Koutsilieris M; Papageorgiou A
    J BUON; 2006; 11(3):323-7. PubMed ID: 17309157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
    Molina JR; Jett JR; Foster N; Lair BS; Carroll TJ; Tazelaar HD; Hillman S; Mailliard JA; Bernath AM; Nikcevich D
    Am J Clin Oncol; 2006 Jun; 29(3):246-51. PubMed ID: 16755177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma.
    Downs LS; Judson PL; Argenta PA; Ghebre R; Geller MA; Bliss RL; Boente MP; Nahhas WA; Abu-Ghazaleh SZ; Chen MD; Carson LF
    Cancer; 2008 Jan; 112(2):331-9. PubMed ID: 18058810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated limb infusion: technique description and clinical application.
    Cronin CG; Lohan DG; O'Riordan C; Gough N; O'Sullivan GJ
    J Vasc Interv Radiol; 2009 Jun; 20(6):837-41. PubMed ID: 19465309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.